FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL): payments to doctors
Payments that named FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $395K
- Providers
- 9,307
- Transactions
- 12,981
- Average per transaction
- $30
The per-transaction average — $30 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,307 providers the average total is $42, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Seqirus USA Inc | $394,644 | 100.0% |